GLP-1 Microdosing, Food Noise, and How to Protect Muscle While Losing Weight

Rocha describes food noise as frequent or intrusive thoughts about what to eat, when to eat, cravings, snacking or grazing, and anticipating the next meal. He points out it is not a formal medical diagnosis, though he says the term describes the experience so well for patients. He compares appetite to a radio station playing loudly all day for some people, and says GLP-1 therapy does not necessarily turn food off, though it may turn that volume down so eating becomes more of a conscious decision rather than a constant negotiation.

Rocha says a patient who responds well to a lower dose inside the normal titration range is not necessarily microdosing, because that dose still sits within normal titration or therapeutic use. A microdose, in his words, usually refers to deliberately using a dose below conventionally studied or labeled therapeutic dosing, and he notes there is no universally accepted medical definition of GLP-1 microdosing. Using tirzepatide as his example, he describes standard dosing running from 2.5 mg up to 15 mg, with a microdose landing somewhere around 10 to 50 percent of that lowest standard dose. He was explicit on the episode that this is education and not personal medical advice.

Rocha says some lean tissue loss is expected whenever significant weight loss happens, so the goal is preserving as much functional skeletal muscle as reasonably possible. He points at a pattern he calls typical, someone handed a GLP-1 after a five to seven minute appointment without much guidance, which he says sets a patient up for failure. His priorities are adequate protein, progressive resistance training, enough calories, good recovery and sleep, stress management, and weight loss that does not come off too quickly, which he puts at about one to two pounds a week as a general rule of thumb. He monitors whether that weight loss is healthy or unhealthy with InBody body composition scans.

Rocha calls that a terrible idea. Even at lower doses these are prescription medications that can affect appetite, digestion, how the body regulates blood sugar, hydration and nutrient intake, so they need medical supervision with labs, vital signs, history and physical exam findings. He also flags dosing confusion as one of the biggest risks with compounded products, since concentrations, vial sizes, syringes and unit to milliliter conversions all vary. He says he spends roughly ten minutes on that topic alone when prescribing, and Med Matrix nursing staff then walk the patient through the vial, the syringe and the injection a second time.

Rocha names pregnancy, and a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, as contraindications. He also weighs significant GI disease, gallbladder or pancreatitis history, eating disorders, nutritional status, other glucose lowering medications, and whether someone can maintain hydration, protein and calorie intake or stay with the monitoring plan. His summary line was that availability does not automatically equal appropriateness of therapy.

No. Rocha says the scale is one outcome among several, and he points to blood sugar and A1C, insulin resistance, visceral fat packed around the organs, triglycerides, blood pressure, cardiovascular risk, fatty liver and mobility. On this episode he takes a minute on insulin resistance, which he describes as the root cause sitting underneath the conditions of metabolic syndrome.